hongkongzh
SI Opener: Investing in health and disease prevention is the best cure

SI Opener: Investing in health and disease prevention is the best cure

06-04-2021 | SI Opener
Covid-19 has put the spotlight on health. But our investment and Active Ownership teams have had a focus on health, health care and healthy food for some years already. We take the good aspects of it, such as the excellent investment opportunities that can be found in disease prevention, pharmaceuticals, fitness, and healthy and plant-based food, with the bad things. For this we are engaging with companies to create new health models that can drive down costs, produce food with less fat, sugar and salt, and fewer antibiotics in the meat supply chain.
  • Masja Zandbergen - Albers
    Masja
    Zandbergen - Albers
    可持續投資整合主管

Speed read

  • Consumer shift towards healthy and sustainably produced food
  • Healthy living and disease prevention is a big investment theme
  • Innovation and digitalization is changing health care management
Climate investing: from urgency to solutions
Climate investing: from urgency to solutions
Read more

The future of food is healthy and sustainable

In the last 50 years, global food production and dietary patterns have changed substantially. Increasing crop yields and improving production have helped improve life expectancy and reduce hunger. However, these benefits are being offset by massive environmental degradation due to unsustainable farming practices, along with health problems ranging from obesity to heart disease, as diets become higher calorie and heavily processed.

According to the World Health Organization, overweight and obesity levels have tripled since 1975, with 39% of adults now overweight and 13% obese. At the same time, 9.2% of adults are underweight. The coexistence of people being overweight and underweight has created a double burden of malnutrition in our world. So, it is safe to say that malnutrition is an issue.

Due to these issues, we are seeing shifts in consumer preferences towards healthier and sustainably produced food1. We find the most attractive investment opportunities in plant-based food and beverages, in meal kits such as those from HelloFresh and Marley Spoon, and in restaurant software. Pure-play food companies in these segments are becoming more relevant to consumers, they operate in a very large market, and have relatively low product penetration. This provides them with excellent growth opportunities. Cultured meat looks promising from an environmental perspective and its production costs are decreasing. Its commercial viability, however, is still unclear.

Challenges remain for food giants because they still derive most of their sales from relatively unhealthy food. They are improving though. We find smaller packaged food companies with a better health and sustainability profile better positioned for now.

How to invest in healthy living

Besides these food trends, Robeco has an investment strategy that is dedicated to investing in companies that support healthy living2. We distinguish between four areas of interest: three are about prevention and one is focused on treatment:

  1. Consumer awareness of healthy nutrition: this very much ties into the future of food and is about investing in ingredients, organic and natural food, but also the companies that provide solutions for food safety and analysis. There is much room for growth as the current market share for organic food in the US, for example, is only 5%. It is, however, growing steadily.
  2. Public awareness of healthy lifestyles: obesity levels are already high, but unfortunately almost one-third of the world has put on weight during the pandemic (including yours truly unfortunately), and the average weight gain has been 6.1 kg!3 So the strategy’s stocks that are related to fitness and activity are doing well. They are mostly in athletic apparel, but also fitness equipment.
  3. Hygiene and consumer health products: another area that is not new to our healthy living strategy, but has become very topical during the pandemic, are hygiene products. Think about oral, hair and skin products, and vitamins and nutritional supplements.
  4. And last but not least, it is not only prevention that is an interesting area, but also the incidence of lifestyle diseases led by ’diabesity’, heart disease, strokes and cancer. We invest in prevention and diagnosis, health care efficiency and chronic care.

The health trend is truly a long-term one. The risk as measured by volatility is relatively low, and the strategy has outperformed the market since its launch in 2007.

Taking the good with the bad

Even though we see this trend towards prevention and healthy living as interesting, the amount of money that is spent on prevention is still only a fraction of the costs of cure. These costs are still rising everywhere and are now almost 17% of GDP in the US!

In the last SI Opener, we explained the role of the meat supply chain4 in threatening global health, and the engagement we are doing with some of the companies in which we invest that are active in the meat supply chain. Here we would like to focus on two other engagement themes that we do in this area.

The first is our engagement on the risks of sugar in food . This three-year engagement closed in 2019, but turned out to be very relevant, as research by the UK’s National Health Service shows that one-third of the people who died from Covid-19 had either Type 1 or Type 2 diabetes, a condition that is often linked to obesity and sugar.

Aside from the health issues, the negative impact on the performance of a company using sugar in its processes can be significant. The costs associated with obesity include increased health care expenses, decreased productivity and premature deaths. Because of this, food and beverage companies face regulatory, reputational, legal and market risks.

Examples of this are governments in both high and lower-income countries that are introducing a sugar tax, or are restricting advertising of less-healthy products to children. Regulation is increasing over the use of health and nutrition claims, while food labelling requirements are being strengthened. Ultimately, companies that do not adjust to changing dietary preferences may lose market share, revenues and profits.

Disrupting the health industry with tele-tools

The second engagement theme concerns digitalization and innovation, which we believe can reduce health care costs. However, a shift in mindset is needed. Will the health care industry be disrupted? Three developments suggest that change is on its way.

Firstly, while health care has traditionally been an industry slow to adopt new technology, it now appears to be embracing digital innovation at a growing rate. Increasingly, there is electronic harmonization of patient data exchange between doctors, health service providers and pharma companies.

Secondly, more companies are open to data exchange between firms to maximize the potential of the insights this can bring. Thirdly, the introduction of telemedicine could reduce the cost and waiting time for patients to receive a consultation from a qualified medical expert.

In addition, pharmaceutical research is increasingly using new technologies such as AI to help reduce the time and costs related to drug development. Recent reforms also indicate a shift from activity-based to outcome-based models, and digitalization can surely further enhance this trend. There are numerous opportunities, from promoting healthy behavior and drug personalization, to remote monitoring, holistic analysis and improved decision making. Digitalization cannot single-handedly solve health care challenges, but it can help in controlling costs, improving quality, and guiding the sector towards more patient-centric care.

Main aim of engagement

The main aim of our engagement is to gain perspective into the current state of the health care industry related to digitalization, and to motivate companies to utilize opportunities as well as to be aware of, and mitigate, their related risks. Within our engagement we will consider the following objectives:

  1. Digital strategy: does the company have a sound digital strategy that is integrated throughout the organization?
  2. Sector collaboration: is the company working together with stakeholders to optimize benefits and mitigate risks coming from digitalization?
  3. Innovation management: how does the company use digitalization to both optimize its processes and in new product development?
  4. Sales and marketing strategy: how does the company use digital technology to improve the quality of its sales and marketing processes?
  5. Cybersecurity: is the company aware of cybersecurity risks and is it doing everything in its power to mitigate those risks?

As with all material ESG issues, we believe that engaging with health care companies will push the sector forward, and will also help us to select for investment portfolios those companies that have a healthy future.

1Robeco white paper: Trends investing, the Future of Food, 24 March 2021, Sam Brasser
2Watch our newest video here: https://www.robeco.com/en/insights/2021/02/we-believe-that-the-trend-around-healthy-living-is-long-lived-.html
3https://www.ipsos.com/en/covid-diet-and-health#:~:text=A%20third%20of%20the%20population,on%20an%20additional%206.1kg.
4https://www.robeco.com/en/insights/2021/02/si-opener-the-meat-supply-chain-is-a-major-threat-to-global-health.html
5https://www.robeco.com/en/insights/2020/07/sugars-role-in-coronavirus-fatalities.html
6Digital innovation in healthcare research report, Robeco Active Ownership team, December 2019

可持續投資系列《開闊視野》
可持續投資系列《開闊視野》
眼見為實
閱讀所有文章

Important information

The contents of this document have not been reviewed by any regulatory authority in Hong Kong. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. This document has been distributed by Robeco Hong Kong Limited (‘Robeco’). Robeco is regulated by the Securities and Futures Commission in Hong Kong.
This document has been prepared on a confidential basis solely for the recipient and is for information purposes only. Any reproduction or distribution of this documentation, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited. By accepting this documentation, the recipient agrees to the foregoing
This document is intended to provide the reader with information on Robeco’s specific capabilities, but does not constitute a recommendation to buy or sell certain securities or investment products. Investment decisions should only be based on the relevant prospectus and on thorough financial, fiscal and legal advice.
The contents of this document are based upon sources of information believed to be reliable. This document is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
Investment Involves risks. Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future. The value of your investments may fluctuate. Past performance is no indication of current or future performance.

Logo

免責聲明

1. 一般事項

請細閱以下資料。 

此網站由Robeco Hong Kong Limited(「荷寶」)擬備及刊發,荷寶是獲香港證券及期貨事務監察委員會發牌從事第1類(證券交易)、第4類(就證券提供意見)及第9類(資產管理)受規管活動的企業。荷寶不持有客戶資產,並受到發牌條件所規限。荷寶在擴展至零售業務之前,必須先得到證監會的批准。本網頁未經證券及期貨事務監察委員會或香港的任何監管當局審閱。

2. 風險披露聲明

Robeco Capital Growth Funds以其特定的投資政策或其他特徵作識別,請小心閱讀有關Robeco Capital Growth Funds的風險:

  • 部份基金可涉及投資、市場、股票投資、流動性、交易對手、證券借貸及外幣風險及小型及/或中型公司的相關風險。
  • 部份基金所涉及投資於新興市場的風險包括政治、經濟、法律、規管、市場、結算、執行交易、交易對手及貨幣風險。
  • 部份基金可透過合格境外機構投資者("QFII")及/或 人民幣合格境外機構投資者 ("RQFII")及/或 滬港通計劃直接投資於中國A股,當中涉及額外的結算、規管、營運、交易對手及流動性風險。
  • 就分派股息類別,部份基金可能從資本中作出股息分派。股息分派若直接從資本中撥付,這代表投資者獲付還或提取原有投資本金的部份金額或原有投資應佔的任何資本收益,該等分派可能導致基金的每股資產淨值即時減少。
  • 部份基金投資可能集中在單一地區/單一國家/相同行業及/或相同主題營運。 因此,基金的價值可能會較為波動。
  • 部份基金使用的任何量化技巧可能無效,可能對基金的價值構成不利影響。
  • 除了投資、市場、流動性、交易對手、證券借貸、(反向)回購協議及外幣風險,部份基金可涉及定息收入投資有關的風險包括信貨風險、利率風險、可換股債券的風險、資產抵押證券的的風險、投資於非投資級別或不獲評級證券的風險及投資於未達投資級別主權證券的風險。
  • 部份基金可大量運用金融衍生工具。荷寶環球消費新趨勢股票可為對沖目的及為有效投資組合管理而運用金融衍生工具。運用金融衍生工具可涉及較高的交易對手、流通性及估值的風險。在不利的情況下,部份基金可能會因為使用金融衍生工具而承受重大虧損(甚至損失基金資產的全部)。
  • 荷寶歐洲高收益債券可涉及投資歐元區的風險。
  • 投資者在Robeco Capital Growth Funds的投資有可能大幅虧損。投資者應該參閱Robeco Capital Growth Funds之銷售文件內的資料﹙包括潛在風險﹚,而不應只根據這文件內的資料而作出投資。

3. 當地的法律及銷售限制

此網站僅供“專業投資者”進接(其定義根據香港法律《證券及期貨條例》(第571章)和/或《證券及期貨(專業投資者)規則》(第571D章)所載)。此網站並非以在禁止刊發或提供此網站(基於該人士的國籍、居住地或其他原因)的任何司法管轄區內的任何人士為對象。受該等禁例限制的人士或並非上述訂明的人士不得登入此網站。登入此網站的人士需注意,他們有責任遵守所有當地法例及法規。一經登入此網站及其任何網頁,即確認閣下已同意並理解以下使用條款及法律資料。若閣下不同意以下條款及條件,不得登入此網站及其任何網頁。

此網站所載的資料僅供資料參考用途。

在此網站發表的任何資料或意見,概不構成購買、出售或銷售任何投資,參與任何其他交易或提供任何投資建議或服務的招攬、要約或建議。此網站所載的資料並不構成投資意見或建議,擬備時並無考慮可能取得此網站的任何特定人士的個別目標、財務狀況或需要。投資於荷寶產品前,必須先細閱相關的法律文件,例如管理法規、基金章程、最新的年度及半年度報告,所有該等文件可於www.robeco.com/hk/zh免費下載,亦可向荷寶於香港的辦事處免費索取。 

4. 使用此網站

有關資料建基於特定時間適用的若干假設、資料及條件,可隨時更改,毋需另行通知。儘管荷寶旨在提供準確、完整及最新的資料,並獲取自相信為可靠的資料來源,但概不就該等資料的準確性或完整性作出明示或暗示的保證或聲明。 

登入此網站的人士需為其資料的選擇和使用負責。 

5. 投資表現

概不保證將可達到任何投資產品的投資目標。並不就任何投資產品的表現或投資回報作出陳述或承諾。閣下的投資價值可能反覆波動。荷寶投資產品的資產價值可能亦會因投資政策及/或金融市場的發展而反覆波動。過去所得的業績並不保證未來回報。此網站所載的往績、預估或預測不應被視為未來表現的指示或保證,概不就未來表現作出任何明示或暗示的陳述或保證。基金的表現數據以月底的交易價格為基礎,並以總回報基礎及股息再作投資計算。對比基準的回報數據顯示未計管理及/或表現費前的投資管理業績;基金回報包括股息再作投資,並以基準估值時的價格及匯率計算的資產淨值為基礎。 

投資涉及風險。往績並非未來表現的指引。準投資者在作出任何投資決定前,應細閱相關發售文件所載的條款及條件,特別是投資政策及風險因素。投資者應確保其完全明白與基金相關的風險,並應考慮其投資目標及風險承受程度。投資者應注意,基金股份的價格及收益(如有)可能反覆波動,並可能在短時間內大幅變動,投資者或無法取回其投資於基金的金額。若有任何疑問,請諮詢獨立財務及有關專家的意見。 

6. 第三者網站

本網站含有來自第三方的資料或第三方經營的網站連結,而其中部分該等公司與荷寶沒有任何聯繫。跟隨連結登入任何其他此網站以外的網頁或第三方網站的風險,應由跟隨該連結的人士自行承擔。荷寶並無審閱此網站所連結或提述的任何網站,概不就該等網站的內容或所提供的產品、服務或其他項目作出推許或負上任何責任。荷寶概不就使用或依賴第三方網站所載的資料而導致的任何虧損或損毀負上法侓責任,包括(但不限於)任何虧損或利益或任何其他直接或間接的損毀。 此網站以外的網頁或第三方網站皆旨在作參考之用。

7. 責任限制

荷寶及(潛在的)其他網站資料供應商概不就此網站內容或其所載的資料或建議負責,而該等內容、資料或建議可予更改,毋需另行通知。 

荷寶並無責任確保及保證此網站的功能將不受干擾或並無失誤。荷寶概不就有關荷寶(交易)服務電郵訊息的後果承擔任何責任,該等電郵訊息可能無法接收或發出、損毀、不正確接收或發出或並無準時接收或發出。 

荷寶亦不就因登入及使用此網站而可能導致的任何虧損或損毀負責。 

8. 知識產權

所有版權、專利、知識產權和其他財產,以及有關此網站資料的授權均由荷寶持有及獲取。該等權利不會轉授予查閱有關資料的人士。 

9. 私隠

荷寶保證將會根據現行的資料保障法例,以保密方式處理登入此網站的人士的數據。除非荷寶需按法律責任行事,否則在未經登入此網站的人士許可,不會向第三方提供該等數據。 請於我們的私隱及Cookie政策 中查找更多詳情。 

10. 適用法律

此網站受香港法律監管及據此解釋。因此網站導致或有關此網站的所有爭議應交由香港法庭作出專有裁決。  

如果您已閱讀並理解本頁並同意上述免責聲明以及同意荷寶收集和使用您的個人資料,用於私隱及Cookie政策 所列的收集和使用個人資料的目的(包括用於直接推廣荷寶的產品或服務),請點擊“我同意”按鈕。否則,請點擊“我不同意”離開本網站。

我不同意